天域生物终止向实控人方不超4.65亿元定增 已连亏6年

Core Viewpoint - Shanghai Stock Exchange has decided to terminate the review of Tianyu Biotechnology Co., Ltd.'s application for issuing shares to specific targets, following the company's request to withdraw the application and the sponsorship from Guohai Securities Co., Ltd. [1] Group 1: Termination of Share Issuance - The Shanghai Stock Exchange accepted Tianyu Biotechnology's application for issuing shares on December 11, 2025, and conducted the necessary review [1] - On February 11, 2026, Tianyu Biotechnology and its sponsor submitted a request to withdraw the application for issuing shares and to revoke the sponsorship [1] - The termination of the review was based on relevant regulations from the Shanghai Stock Exchange [1] Group 2: Financial Performance - Tianyu Biotechnology's planned issuance involved up to 71,028,297 shares, aiming to raise a total of approximately RMB 465.24 million [2] - The funds were intended for supplementing working capital and repaying debts after deducting related issuance costs [2] - The company reported net profits attributable to shareholders of -157.45 million, -214.74 million, -312.19 million, -461.64 million, and -107.36 million RMB for the years 2020 to 2024, respectively [2] - The 2025 annual performance forecast indicates an expected net profit loss of between -125 million and -85 million RMB [2]